To evaluate the possible occurrence of carbapenemase-producing Escherichia coli and Klebsiella spp. strains in domestic animals.
Introduction
The most prevalent mechanism of carbapenem resistance among Enterobacteriaceae is the acquisition of carbapenem-hydrolysing enzymes. Commonly recognized carbapenemases are KPC-, NDMand OXA-48-type enzymes, whose encoding genes are located on conjugative plasmids that are easily transferable between different enterobacterial species. 1 Owing to the emergence of OXA-48-producing Enterobacteriaceae, first in Turkey and afterwards in several other European and non-European countries in the last five years, these bacteria have received increased attention, in particular in hospital facilities as they are frequently associated with serious therapeutic failures. 2, 3 Multidrug resistance in OXA-48 carbapenemase-producing Enterobacteriaceae often results from the coproduction of various b-lactamases, e.g. extended-spectrum b-lactamases (ESBLs) and plasmid-encoded AmpC b-lactamases, and other resistance determinants. 4 Recently, OXA-48-type carbapenemase-producing Klebsiella pneumoniae and Escherichia coli isolates have been isolated in different German hospitals, thus extending the range of countries reporting the emergence of such bacteria. 5 Reports on carbapenemase-producing bacteria in animals are very rare and so far limited to livestock. Several VIM-1 carbapenemase-producing E. coli and Salmonella isolates were isolated from pigs in Germany, 6, 7 one Acinetobacter baumannii isolate expressing carbapenemase OXA-23 was recently recovered from cattle in France, 8 and NDM-1-producing A. baumannii and Acinetobacter lwoffii isolates were reported from porcine and chicken sources in south China. 9 Here, we describe the detection and molecular characterization of OXA-48 carbapenemaseproducing K. pneumoniae and E. coli strains obtained from or along with clinical samples from dogs in a veterinary clinic in Germany in 2012.
Materials and methods

Bacterial isolates and antimicrobial susceptibility testing
Between June 2012 and October 2012, specimens (n¼3885) from urine (n ¼382), faeces (n ¼463), skin and soft tissue (n ¼563), genital tract (n ¼534), respiratory tract (n¼379), internal organs (n¼182) and various other sites (n¼1382) were received from veterinary surgeons and clinicians and processed by standard culture methods. All isolated E. coli (n¼1175) and Klebsiella spp. (n¼109 K. pneumoniae; n¼27 Klebsiella oxytoca) were screened for susceptibility to carbapenems using imipenem and ertapenem disc diffusion testing as recommended by the CLSI. 10, 11 Phenotypic confirmation of carbapenemase production was performed using the modified Hodge test.
12 MIC data were generated by the VITEK w 2 system (bioMér-ieux, Germany; cards AST-N118 and GN-38). Carbapenem-non-susceptible isolates were further tested phenotypically for ESBL production by combination disc tests using ceftazidime and cefotaxime with and without clavulanic acid (Oxoid, Wesel, Germany) according to CLSI guidelines. 11 In addition, a cefoxitin disc (30 mg, Oxoid) was used to detect AmpCphenotypes. All isolates classified as intermediate or resistant to cefoxitin according to CLSI criteria (≤17 mm) were suspected to be AmpC producers.
Identification of b-lactamase genes and other resistance genes
Screening for b-lactamase genes bla OXA-48 , bla VIM , bla NDM-1 , bla IMP and bla KPC , bla CTX-M , bla OXA , bla SHV and bla TEM , bla CMY , bla MOX , bla FOX , bla CIT and bla DHA was carried out using PCR and subsequent sequencing according to previous protocols. 4, 5, 13, 14 The genetic environment of bla OXA-48 was investigated using PCR and sequencing as described previously. 15 The identification of genes qnr-like, qepA, oqxA/B and aac(6 ′ )-Ib encoding plasmidmediated quinolone resistance (PMQR) determinants was carried out as described previously. 14, 16 Conjugation experiments and plasmid characterization Transferability of b-lactam resistance by conjugation was tested by broth mating assays using a sodium azide-resistant E. coli J53 recipient. 17 Plasmids were characterized using S1 nuclease restriction of genomic DNA and subsequent PFGE, 18 as well as PCR-based replicon typing. 19 
Molecular typing of bacterial isolates
Bacterial strain typing of K. pneumoniae and E. coli isolates was performed using XbaI-macrorestriction analysis following a published protocol 14 with interpretation according to the criteria of Tenover et al. 20 Macrorestriction patterns were digitally compared with a collection of previously typed OXA-48-producing isolates from human patients, using BioNumerics Version 6.6 (Applied Maths, Sint-Martens, Belgium). 5 Multilocus sequence typing (MLST) of K. pneumoniae and E. coli isolates was carried out according to published protocols. 21, 22 For gene amplification and sequencing, we used primers specified on the K. pneumoniae (www.pasteur.fr/mlst) and E. coli MLST web sites (http://mlst.ucc.ie/mlst/ mlst/dbs/Ecoli). DNA sequencing was carried out by an external company (LGC Genomics Berlin, Germany) and sequences were analysed using Ridom Seqsphere (Ridom GmbH, Muenster, Germany).
Results and discussion
During a 5 month period in 2012, we isolated carbapenem nonsusceptible K. pneumoniae subsp. pneumoniae (n¼ 5) and E. coli (n¼ 3) isolates from six dogs admitted to a small-animal veterinary clinic in Hessia, Germany ( Table 1 ). The first isolates (K. pneumoniae IHIT 22059 and E. coli IHIT 22060) were recovered from a wound swab of an 11-year-old bulldog with a cardiac pacemaker, exhibiting several comorbidity factors. One day later, bacteriological examination was performed on bronchoalveolar lavage fluid taken from an 8-month-old German shepherd mixed breed dog with eosinophilic pneumonia. Here again, one K. pneumoniae (IHIT 22061) and one E. coli (IHIT 22062) with carbapenem non-susceptibility (Table 2) were isolated. From 21 August to 6 October 2012, another three K. pneumoniae isolates and one E. coli isolate showing carbapenem non-susceptibility were isolated from tracheal washing (IHIT 22063), faeces (IHIT 22064), urine (IHIT 22065) and central venous catheter (IHIT 22066) samples taken from four individual dogs, as shown in Table 1 . Besides carbapenem non-susceptible Enterobacteriaceae, other bacterial species, including methicillin-resistant Staphylococcus pseudintermedius (MRSP), A. baumannii, Streptococcus spp., Enterococcus spp. and ESBL-producing E. coli were recovered from the different sample materials. Thus, with the exception of dog 5 suffering from cystitis, where K. pneumoniae was obtained in pure culture, all the other dogs showed mixed bacterial populations in the samples (Table 1) .
All eight clinical isolates were positive for bla OXA-48 . So far, carbapenemase-producing bacterial isolates have been isolated only occasionally from different livestock animals in Germany, 6, 7 France 8 and China. 9 However, there has been no report on carbapenemases in companion animals and, to our knowledge, none about OXA-48-producing bacteria from an animal source at all. Previous studies on human OXA-48-producing isolates indicate that plasmids carrying the bla OXA-48 gene from different Enterobacteriaceae isolates, clonal groups and geographical regions may share similar characteristics. 2, 4, 23 Common features included self-transferability by conjugation, plasmid size (60-70 kb), absence of additional resistance determinants and the failure to determine the replicon type using the PCR-based replicon typing method. 19 These criteria match the results we obtained in the present study in many aspects ( Table 2 ). All bla OXA-48 -carrying plasmids were transferable by conjugation, had a size of 60 kb and were determined to be of IncL/M-1 replicon type, as previously described. 4 The detection of Tn1999.2, disrupted by IS1R upstream of bla OXA-48 in the animal-derived isolates, hinted towards relevant overlaps with bla OXA-48 -carrying plasmids identified in isolates from human patients in Germany and other countries. 2, 5, 24 This was further confirmed by the regular detection of the three genes repA, traU and parA in all strains and transconjugants, thus sharing further common features with other sequenced IncL/M plasmids from human sources, such as pHK-NDM and pOXA-48a. 24, 25 Besides OXA-48, the present isolates coexpressed ESBLs of the CTX-M-15 (K. pneumoniae, n¼5) or CTX-M-1 type (E. coli, n¼1), as well as SHV-12 (E. coli, n¼2) and/or AmpC b-lactamase CMY-2 (E. coli, n¼2). Furthermore, different PMQR genes (qnrB2, n¼2; aac(6 ′ )1b-cr, n¼8; and oqxA, n¼5) and other b-lactamase genes (bla OXA-1 , bla TEM-1 and bla SHV-28 ) were identified ( Table 2) . Transconjugants received from all clinical isolates in this study harboured either the 60 kb bla OXA-48 -carrying plasmid alone or in addition to OXA-48 carbapenemase in Enterobacteriaceae in dogs OXA-48 carbapenemase in Enterobacteriaceae in dogs a 130 kb plasmid carrying bla TEM-1 (transconjugant from E. coli IHIT 22062 and IHIT 22064). All transconjugants were resistant to ampicillin and ertapenem, but remained susceptible to thirdgeneration cephalosporins (cefotaxime and ceftazidime). The MIC range of the transconjugants was 1-2 mg/L for imipenem and 0.25-1 mg/L for meropenem, respectively. The two transconjugants positive for bla OXA-48 and bla TEM-1 were additionally resistant to sulfamethoxazole/trimethoprim and the transconjugant of E. coli IHIT 22062 showed increased MIC values for ciprofloxacin (MIC CIP ¼0.25 mg/L). Subsequently performed PCR revealed the presence of PMQR gene qnrB2 in this transconjugant.
MLST and macrorestriction analysis showed a clonal spread of K. pneumoniae sequence type ST15 pulsotype 1 with CTX-M-15 and of E. coli ST1196 pulsotype 2 with CMY-2 and SHV-12. For dogs 1 and 2, these clones emerged in combination, whereas dogs 3, 5 and 6 only harboured ST15 K. pneumoniae (Table 2 ). In contrast to the ST1196 E. coli isolates, the E. coli strain isolated from dog 4 had a different resistance profile, harboured CTX-M-1 instead of CTX-M-15 and did not possess qnrB2. Here, we identified a distinct PFGE type (pulsotype 3), and sequence type ST1431, which differed in five out of seven alleles from ST1196. At this time, one can only speculate whether our finding reflects an ongoing in vivo transfer of the bla OXA-48 -carrying plasmid to other, so far non-affected, bacterial strains and species or the spread of a novel strain that is already bla OXA-48 positive. None of the sequence types identified among the canine E. coli strains resembled previously reported OXA-48-producing clones, like ST38 24 -26 and ST131. 24, 27 According to the literature and data available from the E. 35, 36 and ST395. 37 Recently, a K. pneumoniae ST15 isolate possessing bla OXA-48 and bla TEM-1 was identified along with faecal screening of a human patient in Finland, albeit with history of travel to Thailand, suggesting that strains of this sequence type are probably prone to acquire different resistance plasmids. 26 The previous detection of K. pneumoniae ST15 with CTX-M-15, TEM-1 and OXA-1 in veterinary clinic-acquired urinary tract infections in cats and dogs in France further underlines that this clone might be on its way to extend its global success from the medical to the veterinary area. 38 In the USA and Europe, an estimated proportion of 8% of all nosocomial infections in humans are caused by K. pneumoniae.
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Mainly due to the spread of Enterobacteriaceae strains that produce ESBLs, carbapenems have become antimicrobial agents of last resort and hence these substances are critical for the prevention and treatment of life-threatening infections. 39 In Germany, carbapenems are licensed neither for the treatment of livestock nor for that of companion animals or pets in general. However, for small-animal populations or for rare infectious diseases, effective antimicrobials may simply not be available due to lack of approval and so there is the opportunity for off-label use under specific circumstances. 40 This, with respect to animal welfare, exclusively refers to life-threatening diseases and, in the case of bacterial infections, those resistant to treatment with cephalosporins and other antimicrobial substances. However, off-label usage of carbapenems is not common practice at the veterinary clinic where we obtained the OXA-48 producers, evidenced by the history of antimicrobial treatment of the dogs, which is documented in Table 1 . Although we cannot rule out that carbapenems had been administered to the dogs once in their lifetime, it seems more likely that they had undergone nosocomial colonization rather than experienced in vivo selection of OXA-48-producers driven by antibiotic treatment. This is further supported by the fact that all dogs except for dog 2, which was, however, previously housed together with dog 1, were kept in the intensive care unit for at least 24 h during their stay in the veterinary clinic, hinting towards a common environmental source. Efforts are currently under way to determine whether the maintenance of multidrug-resistant enterobacterial isolates might be owing to an undetected hygiene problem or putative human carriers (veterinary personnel or surgeons). So far, OXA-48-producing isolates have mainly appeared as colonizers rather than as primary or sole aetiological agents, almost always correlated with comorbidities in the patients.
In conclusion, we report the emergence and clonal spread of K. pneumoniae and E. coli producing carbapenemase OXA-48 in dogs. Since resistance to carbapenems is not commonly tested for in veterinary clinical isolates, non-susceptible isolates are probably underreported. Due to the increasingly frequent finding of carbapenemase-producing Enterobacteriaceae in humans, and their still sporadic occurrence in animals, a transfer from humans to animals appears highly probable. The present findings add to a growing number of reports on multidrug-resistant strains from human and animal sources-a concerning development that needs constant attention and further investigations. made use of the Klebsiella pneumoniae MLST web site (http://pubmlst. org/kpneumoniae) developed by Keith Jolley and sited at the University of Oxford. 41 The development of that site has been funded by the Wellcome Trust.
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